Leidos and the University of Pittsburgh Join Forces to Improve Disease Detection
Leidos (NYSE: LDOS) has announced a groundbreaking investment of $10 million aimed at utilizing artificial intelligence (AI) for the detection and management of diseases. This initiative will be in collaboration with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence (CPACE).
The primary focus of this five-year partnership is to enhance the speed and accuracy of disease detection, targeting ailments such as heart disease and cancer. Through this investment, Leidos hopes to reduce diagnostic turnaround times significantly and improve care management practices.
Tom Bell, the CEO of Leidos, emphasized the transformative potential of AI, stating, ‘Our investment is aimed at using the transformative power of artificial intelligence to speed detection, diagnosis and treatment of diseases that affect millions of people annually.’ He further mentioned that the partnership would also focus on nurturing future healthcare specialists and extending care to underserved populations, including veterans.
Significance of the Partnership
Leidos has been a longstanding supporter of cancer research, having operated the National Cancer Institute’s Frederick National Laboratory for over 25 years. With decades of experience in applying AI across various sectors including healthcare, national security, and energy, this new venture aims to enhance care for military families while strengthening the continuity of healthcare delivery.
Key Objectives of Collaboration
- Creating a Research Hub: The University of Pittsburgh will advance CPACE by developing a cutting-edge Digital Pathology Research Center, fostering innovative research in digital pathology and AI-driven diagnostics.
- Pioneering Digital Health Solutions: This partnership will help in enhancing AI technologies that will help in developing new solutions for digital health and diagnostics.
- Global Impact: Leidos aims to leverage this collaboration to deploy AI-powered digital pathology solutions across various sectors, advancing innovative healthcare technologies.
Anantha Shekhar, senior vice chancellor for health sciences at the University of Pittsburgh, affirmed the partnership’s potential, stating, ‘The University of Pittsburgh’s leadership in research and innovation, coupled with the expertise in technology solutions offered by Leidos, establishes a path forward to delivering advancements in diagnosis, disease management and health care delivery.’
Enhancing Workforce Development
This joint venture will also focus on developing the workforce of the future by creating educational opportunities in health care and AI. This includes industry-specific best practices, symposiums, and hands-on internships allowing students to work alongside Leidos experts.
Hooman Rashidi, executive director of CPACE, pointed out: ‘We want these tools to impact as many people as possible globally. Leidos can help get them into many more hands, ensuring that they are validated properly.’
By integrating academic expertise with technological innovation, this partnership stands to significantly reshape the future of healthcare delivery and disease management.
Liron Pantanowitz, Dr. Maud L. Menten Professor at the University of Pittsburgh, echoed this sentiment by stating, ‘This relationship with Leidos serves as a catalyst to expedite our mission.’
- 0 Comments
- Disease Detection
- Leidos
- University of Pittsburgh